Loading...

Cara Therapeutics, Inc.

CARA•NASDAQ
Healthcare
Biotechnology
$5.32
$-0.14(-2.56%)

Cara Therapeutics, Inc. (CARA) Stock Overview

Explore Cara Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 70.3/100

Key Financials

Market Cap8.1M
P/E Ratio-179.88
EPS (TTM)$-46.59
ROE499.47%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 Months$0.00
1 Year Target$3.31

CARA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Cara Therapeutics, Inc. (CARA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $3.31.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -179.88 and a market capitalization of 8.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
-65.96%
↓ 65.96%
Profit Growth
$-0.03
↑ 40.20%
EPS Growth
$-0.03
↑ 99.29%
Operating Margin
-364.88%
↑ 51.95%
ROE
49946.81%
↑ 40.20%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
Buy
Hold
Sell
Strong Sell

Price Targets

Low$1.00
Average$1.00
High$1.00

Company Profile

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

CEO

Christopher A. Posner

Employees

10

Headquarters

4 Stamford Plaza, Stamford, CT

Founded

2014

Frequently Asked Questions

;